Viking Global Investors LP (“Viking”) is a global investment firm founded in 1999.  We employ a fundamentals-driven investment approach to managing over $46 billion of capital across public equity, private equity, and credit and structured capital strategies.  Across our funds, our primary goal is to provide investors with best-in-class performance.  We believe operational excellence is essential to our management of the capital with which we have been entrusted.  We have more than 275 employees, including more than 45 investment professionals, across five offices: Stamford, New York, Hong Kong, London and San Francisco.  We seek to attract people who exhibit our Firm’s core values of intellectual honesty, integrity, continuous improvement, and accountability.  Viking is registered as an investment adviser with the U.S. Securities and Exchange Commission. Please be aware that Viking’s name, brand, and reputation may be misused by unauthorized third parties. We do not provide investment advice or otherwise solicit capital via social media, including LinkedIn and Facebook, or encrypted chat platforms, including Telegram, WhatsApp, or Signal. If you receive a communication that appears suspicious, please report it to us at legalnotices@vikingglobal.com.

Zentalis Pharmaceuticals

Birchbox

BridgeBio

Cazoo

Ginkgo Bioworks

Icosavax

Moderna

Pepgen

Roivant Sciences

PROCEPT BioRobotics

Sema4

Credit Karma

Day One Biopharmaceuticals

Deciphera Pharmaceuticals

Edgewise Therapeutics

AbCellera

Adaptive Biotechnologies

Affinivax

Amunix

Amylyx Pharmaceuticals

Athira Pharma

Editas Medicine

Standard BioTools

Auris Health

Viking Global Investors

Viking Global Investors is an investment firm that manages assets for a range of clients including endowments, foundations, pension plans, and sovereign wealth funds. The firm employs a research-intensive approach to identify opportunities across geographies and sectors.

COM:VIKINGGLOBAL

Viking Global Investors

Filings Not Available